Menopause in the workplace statistics: lost productivity and the cost of untreated symptoms

She was 51, a project director, and three months into night sweats that soaked through her clothes during afternoon status meetings. She had started keeping a blazer on the back of her chair year-round so she could cover the dampness without explaining it. At her annual exam she said her periods were "a little irregular" and left out the part about leaving work early twice that month because brain fog made a client presentation feel impossible. When I asked directly about hot flashes at work, she looked relieved and then angry that no one had asked sooner.

Menopause is not a private health issue that stops at the office door. In the United States, the average age of menopause is 52, according to the Office on Women's Health, which means the transition lands squarely in the years when many women hold senior roles, earn peak wages, and carry caregiving loads outside work. The economic research is clearer now than it was a decade ago. The figure reporters quote most often comes from a 2023 Mayo Clinic Proceedings analysis: about $1.8 billion a year in lost U.S. work time from menopause symptoms, rising to roughly $26.6 billion when related medical expenses are added.

This article pulls together the national statistics that matter for clinicians, HR leaders, and journalists on deadline: how large the menopausal workforce is, what symptoms cost in missed days and presenteeism, how often employers offer real support, and how wide the treatment gap remains for vasomotor symptoms that are, in many cases, treatable.

How many working women are in the menopause years

The first number to get straight is not a dollar figure. It is how ordinary menopause is inside the paid labor force.

A 2025 RAND research report estimated that about 30% of women in the U.S. labor force are in the age range that corresponds with the menopause transition (ages 45 to 60). State-level estimates in that analysis ranged from 22.6% in Washington, D.C., to 32.5% in Vermont. Those are not fringe shares. They describe a core block of experienced workers.

Bureau of Labor Statistics data for 2024 show how strongly women remain attached to paid work through midlife. The employment-population ratio for women ages 45 to 54 was 74.7%, and for women ages 55 to 64 it was 58.8%. The Society for Women's Health Research, citing BLS data, notes that more than 75% of women participate in the labor force during the menopause transition years. Most are working or recently attached to work when they reach menopause.

Timing matters. Perimenopause often begins in the mid- to late 40s; the Office on Women's Health puts average menopause at age 52. That window overlaps with promotions, peak earnings, and heavy caregiving. If you are tracking cycle changes, a period calculator or cycle-length tracker can document irregularity for a clinical visit. For day-to-day symptom context, see our guide to perimenopause symptoms.

The Mayo Clinic cost estimate

The statistic that has traveled farthest in business and health reporting is the Mayo Clinic workplace estimate.

In a 2023 study published in Mayo Clinic Proceedings, Faubion and colleagues surveyed women ages 45 to 60 who received primary care at Mayo Clinic sites. Of 4,440 employed respondents, 13.4% reported at least one adverse work outcome related to menopause symptoms. About 10.8% reported missing work in the preceding 12 months because of those symptoms, with a median of 3 days missed. Symptom severity tracked tightly with work harm: women in the highest quartile of Menopause Rating Scale scores were 15.6 times more likely to report an adverse work outcome than women in the lowest quartile.

From the missed workdays alone, the authors estimated an annual U.S. loss of $1.8 billion. Coverage of the study has reported a combined annual figure of about $26.6 billion when medical expenses associated with menopause symptoms are added. That larger total is the one many HR and benefits stories quote.

Caveats belong next to the headline. The Mayo sample was predominantly White and married, with most participants highly educated. That means the national dollar extrapolation rests on wage and workforce assumptions. The $1.8 billion figure reflects absenteeism. It does not fully capture presenteeism, reduced hours, missed promotions, job changes or early retirement. The published estimate is already large. It is still incomplete.

RAND's 2025 analysis, using a different method, put annual productivity losses at $5.4 billion as a conservative lower bound that still excludes early retirement and missed promotions. The two figures are not directly comparable, but both show that untreated symptoms carry a measurable national cost.

Absenteeism, presenteeism, and career decisions

Missed days are the easiest outcome to count. They are not the only one that matters.

In the Mayo Clinic survey, roughly 1 in 9 employed midlife women reported missing work for menopause symptoms in a single year. The median was only 3 days. That sounds minor until you multiply it nationally and add the days women do not take because they fear being labeled unreliable. Presenteeism (being at work while performing below capacity) is harder to measure and often larger.

A 2013 analysis in Menopause by Whiteley and colleagues used U.S. National Health and Wellness Survey data to compare postmenopausal women by vasomotor symptom severity. Among employed women, adjusted presenteeism was 24.28% for severe symptoms and 14.3% for moderate symptoms, compared with 4.33% for mild symptoms. Severity, not the mere presence of hot flashes, drove the work gaps.

Career decisions sit further downstream. The Society for Women's Health Research EMPACT Menopause Study found that about 1 in 4 women considered not pursuing or did not pursue a leadership opportunity; about 1 in 3 considered reducing or reduced their workload; and about 2 in 5 considered finding or found a new job. Those are self-reported figures, not payroll records, but they match what clinicians hear: women rearrange careers around symptoms more often than workplaces rearrange around women.

A Carrot Fertility survey of 1,000 people with current or recent menopause experience reported that 54% had dealt with menopause-driven work challenges. Among those who took time off, 71% lost more than 40 hours. Nearly 1 in 5 (19%) had considered changing jobs for better support, with higher rates among non-White respondents (28% versus 16%). The sample is not census-grade. Still, the pattern matches Mayo and EMPACT. Symptoms change attendance and job choices, including performance at work. Sleep is often the hidden driver; see our sleep disorders statistics for women.

Employer accommodations remain rare

If the economic case is this clear, why do so few workplaces treat menopause as a standard occupational health issue?

EMPACT data offer a blunt answer. Sixty-one percent of employees and 70% of supervisors said no formal menopause-specific policies were in place. Another large share were unsure whether resources existed at all. Fifty-nine percent of women reported feeling uncomfortable asking for accommodations, and only 31% felt comfortable talking about menopause symptoms at work. One in six supervisors said they were uncomfortable setting up accommodations for employees' menopause symptoms.

The Carrot survey paints a similar employer-side gap. Only 8% of respondents said their employer had offered significant menopause support; 59% reported no support at all. Among the 21% who reported any significant or minor support, flexible scheduling or work-from-home options were the most common resource.

What women need is usually not elaborate: temperature control, cool water, flexible breaks, remote options on bad days, and managers who do not demand a public explanation. The barrier is less inventing accommodations than naming menopause as a legitimate reason to use them. Pregnancy and breastfeeding have clearer U.S. statutory frameworks than menopause; employers that already redesign work for migraine or caregiving leave have templates they can adapt now.

Medical costs and the treatment gap

The workplace bill and the medical bill are linked. Women with bothersome symptoms use more outpatient care, try more therapies, and still often remain undertreated for the symptoms most likely to disrupt work: hot flashes and night sweats.

Vasomotor symptoms affect as many as 80% of midlife women, according to Khan and colleagues in a 2023 review in the International Journal of Women's Health. The same review notes that only about one in four women receive treatment. It also cites a U.S. survey of 1,039 women ages 40 to 65 in which 73% had not received treatment for vasomotor symptoms. That is the treatment gap that turns a manageable endocrine transition into a multi-year productivity problem.

Duration compounds the cost. In the Study of Women's Health Across the Nation (SWAN), Avis and colleagues found that frequent vasomotor symptoms lasted a median of 7.4 years overall. Among women with an observable final menstrual period, symptoms persisted a median of 4.5 years after that period. African American women reported the longest total duration, a median of 10.1 years. A short "wait it out" strategy is not a clinical plan for a worker who may face nearly a decade of disrupted sleep and concentration.

Hormone therapy remains the most effective treatment for vasomotor symptoms for many eligible women. Yet use collapsed after early Women's Health Initiative reports and has not recovered to match current guideline nuance. Training is part of the bottleneck. In a 2019 Mayo Clinic Proceedings survey of family medicine, internal medicine, and obstetrics and gynecology residents, only 6.8% felt adequately prepared to manage menopause. One in five reported receiving no menopause lectures during residency. About a third said they would not offer hormone therapy to a symptomatic, newly menopausal woman without contraindications. Major societies generally consider benefits to outweigh risks for that group when therapy is individualized.

For prescribing trends and candidacy, see our companion piece on menopause and hormone therapy statistics. Nonhormonal options exist (SSRIs/SNRIs, gabapentin, newer neurokinin antagonists) but only help women who are offered them. Women with more severe vasomotor symptoms also make more menopause-related physician visits, as Whiteley and colleagues documented. When medical expenses are added to Mayo's lost-work estimate, the combined annual U.S. figure rises to about $26.6 billion. Quote that total with the $1.8 billion absenteeism component named next to it.

What symptoms cost at the desk

Not every menopause symptom hits work the same way. The ones that collide hardest with paid labor are sleep disruption, vasomotor episodes during meetings, brain fog, mood changes and joint pain in standing or long-shift roles. EMPACT respondents ranked sleep problems and brain fog among the most bothersome workplace symptoms. Carrot respondents most often named hot flashes, trouble sleeping, fatigue and night sweats. These are the same symptoms guidelines already prioritize for treatment. That is why the treatment gap is also a labor-market gap.

Sector matters. RAND found that healthcare and education bear especially high economic burdens because they employ large numbers of women in the menopause-age range. California and Texas had the largest absolute losses. That reflects population and wages more than unique biology. Mood symptoms can intensify around the transition and interact with sleep loss; broader context is in our women's mental health statistics. Longer-term skeletal risk after menopause is covered separately in our osteoporosis statistics.

What would move the numbers

The data do not require a single silver bullet. They require fewer women spending years untreated while workplaces treat symptoms as rare.

Clinically, the levers are familiar: ask about work impact at midlife visits; treat bothersome vasomotor symptoms; update hormone-therapy counseling for eligible women under 60 and within 10 years of menopause; offer nonhormonal options when hormones are declined or contraindicated; and fix the residency training gap Kling documented. A woman who cannot sleep through the night will not "power through" a decade of presenteeism without cost.

For employers, low-friction supports work: flexible scheduling, temperature and uniform flexibility, manager training that reduces stigma, and leave language that does not force cover stories. EMPACT and Carrot both show silence is currently the default. Silence is expensive.

For journalists, the cleanest quote remains the Mayo Clinic pair: roughly $1.8 billion a year in lost U.S. work time from menopause symptoms, and about $26.6 billion when medical expenses are included. Name the primary source next to the number, note the sample limits, and add that RAND's separate $5.4 billion productivity estimate is a lower bound that still leaves out early labor-force exits. The patient with a blazer for camouflage is not competing with the national data. She is what those data look like at human scale.

Frequently asked questions about menopause in the workplace

How much do menopause symptoms cost the U.S. economy each year?

A 2023 Mayo Clinic Proceedings study estimated about $1.8 billion a year in lost U.S. work time from missed workdays related to menopause symptoms. When medical expenses associated with those symptoms are included, reporting on the same body of work cites a combined annual figure of about $26.6 billion. A separate 2025 RAND analysis estimated $5.4 billion in productivity losses as a conservative lower bound.

What share of working women are in the menopause transition years?

RAND estimated in 2025 that about 30% of women in the U.S. labor force are ages 45 to 60, the range corresponding to the menopause transition. BLS data for 2024 show an employment-population ratio of 74.7% for women ages 45 to 54, and the Society for Women's Health Research notes that more than 75% of women participate in the labor force during those transition years.

How often do menopause symptoms cause women to miss work?

In the Mayo Clinic survey of employed women ages 45 to 60, 10.8% reported missing work in the prior 12 months because of menopause symptoms, with a median of 3 days missed. Overall, 13.4% reported at least one adverse work outcome related to symptoms. Women with the most severe symptom scores were far more likely to report work problems than those with mild scores.

Do employers commonly offer menopause accommodations?

Usually not. In the SWHR EMPACT Menopause survey, 61% of employees said their workplaces had no formal menopause-specific policies, and 59% felt uncomfortable asking for accommodations. Only 31% felt comfortable discussing symptoms at work. A Carrot Fertility survey found that 59% of respondents reported no employer menopause support at all, while 21% reported any support.

How common is the treatment gap for hot flashes and night sweats?

Vasomotor symptoms affect as many as 80% of midlife women, but only about one in four receive treatment, according to a 2023 review by Khan and colleagues. A U.S. survey cited in that review found that 73% of women ages 40 to 65 had not received treatment for vasomotor symptoms. Frequent symptoms can last a median of more than 7 years, per SWAN data.

Are residency programs preparing doctors to manage menopause?

Many are not doing enough. In a 2019 Mayo Clinic Proceedings survey of family medicine, internal medicine, and OB/GYN residents, only 6.8% felt adequately prepared to manage menopause, and 20.3% reported receiving no menopause lectures in residency. About 34% said they would not offer hormone therapy to a symptomatic, newly menopausal woman without contraindications.